Close Menu

NEW YORK (GenomeWeb) – Gene-editing technology company Inscripta announced today that its has closed a $55.5 million Series C funding round.

The round was led by Mérieux Développement and Paladin Capital Group, and included existing Inscripta investors Venrock, Foresite, MLS Capital, and NanoDimension.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.